USPTO serial 76396579
AFFILIN
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Feb 12, 2008
- Examiner
- KIM, YONG OH
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active. Evaluate filing a new application if you still use the mark, or petition if cancellation was erroneous. Consult counsel on remaining common-law rights.
Need help with AFFILIN?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Richard E. Jenkins
RICHARD E. JENKINS JENKINS & WILSON, P.A.SUITE 1200 UNIVERSITY TOWER3100 TOWER BOULEVARDDURHAM, NC 27707Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | chemical preparations, namely, artificial binding molecules in the nature of proteins and peptides for use in the environmental industry, biotechnological industry, food industry, cosmetic industry, and gmp production; chemical substances, namely biologically active proteins and peptides with antibody-like binding activities for use in the environmental industry, biotechnological industry, food industry, cosmetic industry, and gmp production; diagnostic reagents and analytical reagents for scientific research use or for use in the biotechnological industry, pharmaceutical industry, food industry, cosmetic industry, and gmp production or for laboratory use or for purification or depletion of chemical or biological substances | SECTION 8 - CANCELLED | — |
| 005 | PHARMACEUTICAL PREPARATIONS FOR USE IN THE TREATMENT OF CYSTIC FIBROSIS, PSYCHOSOMATIC DISEASES, DEPRESSION, EPILEPSY, ENDOCRINOLOGIC DISORDERS, CIRRHOSES, DISEASES ASSOCIATED WITH HORMONAL DISTURBANCES, AUTOIMMUNE DISEASES, EYE DISEASES, OBESITY, METABOLIC DISEASES, STROKE, INFECTIOUS DISEASES, CANCER, DEGENERATIVE DISEASES, NEURODEGENERATIVE DISEASES, ASTHMATIC DISEASES, DERMATOLOGIC DISEASES, MUSCULOSKELETAL DISEASES, PERIODONTOSIS, DENTAL DISEASES, DIABETES, CARDIOVASCULAR DISEASES, INFLAMMATORY DISEASES, HEMATOLOGIC DISEASES, UROLOGIC DISEASES OR ERECTILE DYSFUNCTIONS, PSYCHOLOGICAL DISEASES, BRONCHOLYTIC DISEASES, PULMONARY DISEASES, DERMATOLOGICAL DISEASES, LIPID METABOLISM DISORDERS, MIGRAINE, DEMENTIA, RHEUMATIC DISORDERS, GASTRIC AND INTESTINAL DISEASES, ENZYME DEFICIENCY AND TRANSPORT PROTEINS DISORDERS, ANALEPTIC DISEASES, ANORETIC DISEASES, BLOOD DISEASES, ALLERGIC DISEASES, ANEMIC DISEASES, GERIATRIC DISEASES, COLD AND FLU, HEPATIC DISEASES, IMMUNOLOGICAL DISEASES, CARDIAC DISEASES, SKELETAL AND MUSCLE DISEASES, OSTEOPOROSIS, OTOLOGICAL DISEASES, MOUTH AND PHARYNGEAL DISEASES, ASTHMATIC DISEASES, BILE-DUCT DISORDERS, AND ARTERIOSCLEROSIS; VETERINARY PREPARATIONS FOR USE IN THE TREATMENT OF CYSTIC FIBROSIS, PSYCHOSOMATIC DISEASES, DEPRESSION, EPILEPSY, ENDOCRINOLOGIC DISORDERS, CIRRHOSES, DISEASES ASSOCIATED WITH HORMONAL DISTURBANCES, AUTOIMMUNE DISEASES, EYE DISEASES, OBESITY, METABOLIC DISEASES, STROKE, INFECTIOUS DISEASES, CANCER, DEGENERATIVE DISEASES, NEURODEGENERATIVE DISEASES, ASTHMATIC DISEASES, DERMATOLOGIC DISEASES, MUSCULOSKELETAL DISEASES, PERIODONTOSIS, DENTAL DISEASES, DIABETES, CARDIOVASCULAR DISEASES, INFLAMMATORY DISEASES, HEMATOLOGIC DISEASES, UROLOGIC DISEASES OR ERECTILE DYSFUNCTIONS, PSYCHOLOGICAL DISEASES, BRONCHOLYTIC DISEASES, PULMONARY DISEASES, DERMATOLOGIC DISEASES, LIPID METABOLISM DISORDERS, MIGRAINE, DEMENTIA, RHEUMATIC DISORDERS, GASTRIC AND INTESTINAL DISEASES, ENZYME DEFICIENY AND TRANSPORT PROTEINS DISORDERS, ANALEPTIC DISEASES, ANORETIC DISEASES, BLOOD DISEASES, ALLERGIC DISEASES, ANEMIC DISEASES, GERIATRIC DISEASES, COLD AND FLU, HEPATIC DISEASES, IMMUNOLOGICAL DISEASES, CARDIAC DISEASES, SKELETAL AND MUSCLE DISEASES, OSTEOPOROSIS, OTOLOGICAL DISEASES, MOUTH AND PHARYNGEAL DISEASES, ASTHMATIC DISEASES, BILE-DUCT DISORDERS, AND ARTERIOSCLEROSIS; MEDICAL, DIAGNOSTIC, CHEMICAL AND ANALYTIC REAGENTS FOR USE IN THE TREATMENT OF CYSTIC FIBROSIS, PSYCHOSOMATIC DISEASES, DEPRESSION, EPILEPSY, ENDOCRINOLOGIC DISORDERS, CIRRHOSES, DISEASES ASSOCIATED WITH HORMONAL DISTURBANCES, AUTOIMMUNE DISEASES, EYE DISEASES, OBESITY, METABOLIC DISEASES, STROKE, INFECTIOUS DISEASES, CANCER, DEGENERATIVE DISEASES, NEURODEGENERATIVE DISEASES, ASTHMATIC DISEASES, DERMATOLOGIC DISEASES, MUSCULOSKELETAL DISEASES, PERIODONTOSIS, DENTAL DISEASES, DIABETES, CARDIOVASCULAR DISEASES, INFLAMMATORY DISEASES, HEMATOLOGIC DISEASES, UROLOGIC DISEASES OR ERECTILE DYSFUNCTIONS, PSYCHOLOGICAL DISEASES, BRONCHOLYTIC DISEASES, PULMONARY DISEASES, DERMATOLOGIC DISEASES, LIPID METABOLISM DISORDERS, MIGRAINE, DEMENTIA, RHEUMATIC DISORDERS, GASTRIC AND INTESTINAL DISEASES, ENZYME DEFICIENCY AND TRANSPORT PROTEINS DISORDERS, ANALEPTIC DISEASES, ANORETIC DISEASES, BLOOD DISEASES, ALLERGIC DISEASES, ANEMIC DISEASES, GERIATRIC DISEASES, COLD AND FLU, HEPATIC DISEASES, IMMUNOLOGICAL DISEASES, CARDIAC DISEASES, SKELETAL AND MUSCLE DISEASES, OSTEOPOROSIS, OTOLOGICAL DISEASES, MOUTH AND PHARYNGEAL DISEASES, ASTHMATIC DISEASES, BILE-DUCT DISORDERS, AND ARTERIOSCLEROSIS; AND DIAGNOSTIC PREPARATIONS FOR CLINICAL AND MEDICAL LABORATORY USE | SECTION 8 - CANCELLED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Scil Proteins GmbH
- Other trademarks owned by Scil Proteins GmbH
- Other trademarks owned by Scil Proteins GmbH
- Other trademarks in Class 001
- Other trademarks in Class 005
- Similar marks named AFFILIN
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Sep 19, 2014 | C8.. | CANCELLED SEC. 8 (6-YR) | — |
| Feb 12, 2008 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jan 9, 2008 | OP.T | OPPOSITION TERMINATED NO. 999999 | — |
| Jan 8, 2008 | OP.D | OPPOSITION DISMISSED NO. 999999 | — |
| Jun 5, 2007 | DOCK | ASSIGNED TO EXAMINER | — |
| Dec 5, 2005 | OP.I | OPPOSITION INSTITUTED NO. 999999 | — |
| Jun 30, 2005 | ETOF | EXTENSION OF TIME TO OPPOSE RECEIVED | — |
| Jun 7, 2005 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| May 18, 2005 | NPUB | NOTICE OF PUBLICATION | — |
| Feb 16, 2005 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Feb 11, 2005 | ALIE | ASSIGNED TO LIE | — |
| Jan 24, 2005 | ALIE | ASSIGNED TO LIE | — |
| Dec 21, 2004 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jul 19, 2004 | CNFR | FINAL REFUSAL MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| May 14, 2004 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| May 14, 2004 | PAPER RECEIVED | — | |
| Nov 13, 2003 | CNSI | INQUIRY AS TO SUSPENSION MAILED | — |
| Oct 23, 2003 | CFIT | CASE FILE IN TICRS | — |
| Apr 2, 2003 | CNSL | LETTER OF SUSPENSION MAILED | — |
| Feb 19, 2003 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Feb 19, 2003 | PAPER RECEIVED | — | |
| Aug 26, 2002 | CNRT | NON-FINAL ACTION MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 8, 2002 | DOCK | ASSIGNED TO EXAMINER | — |